NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells

被引:83
作者
Wang, Xun [1 ]
Wang, Yiguang [1 ]
Chen, Xiaomei [1 ]
Wang, Jiancheng [1 ]
Zhang, Xuan [1 ]
Zhang, Qiang [1 ]
机构
[1] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
关键词
NGR; CD13; Docetaxel; Polymeric micelles; CD13-overexpressing tumor; AMINOPEPTIDASE-N; POLYMERIC MICELLES; DRUG-DELIVERY; PEPTIDES; BINDING; FORMULATION; COPOLYMERS; DOCETAXEL; CISPLATIN; CARRIERS;
D O I
10.1016/j.jconrel.2009.05.030
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Certain tumor cells and most tumor endothelial cells overexpress a membrane-spanning molecule, aminopeptidase N (CD13) isoform, which is the receptor for peptides containing the Asn-Gly-Arg (NGR) motif. NGR-modified docetaxel (DTX)-loaded PEG-b-PLA polymeric micelles (NGR-PM-DTX) were firstly developed and tested in vitro and in vivo, while DTX-loaded polymeric micelles (PM-DTX) and free DTX were used as controls. The NGR-PM-DTX containing DTX were about 35 nm in diameter with spherical shape and high encapsulation efficiency. It was demonstrated quantitatively by the spectrophotofluorometry and qualitatively by the confocal image analysis that NGR facilitates the uptake of micelles by CD13-overexpressed tumor cells (fibrosarcoma, HT1080) and endothelial cells (human umbilical vein endothelial cells. HUVEC). Free NGR inhibited cellular uptake of NGR-PM-DTX, revealing the mechanism of receptor-mediated endocytosis. Higher cytotoxicity, toward HT1080 cells and more efficient inhibition of HUVEC proliferation were also observed in NGR-PM-DTX groups, which were consistent well with the observation of cellular uptake. In BALB/c mice bearing HT1080 tumor xenografts, stronger antitumor efficacy and less body weight changes were shown in NGR-PM-DTX group, with good correlation between in vitro and in vivo. Therefore, it was concluded that NGR-PM could be a potential vehicle for delivering hydrophobic chemotherapeutic agents to CD13-overexpressing tumors. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:56 / 62
页数:7
相关论文
共 29 条
  • [21] Pharmacological effects of formulation vehicles - Implications for cancer chemotherapy
    ten Tije, AJ
    Verweij, J
    Loos, WJ
    Sparreboom, A
    [J]. CLINICAL PHARMACOKINETICS, 2003, 42 (07) : 665 - 685
  • [22] A doxorubicin-CNGRC-peptide conjugate with prodrug properties
    van Hensbergen, Y
    Broxterman, HJ
    Elderkamp, YW
    Lankelma, J
    Beers, JCC
    Heijn, M
    Boven, E
    Hoekman, K
    Pinedo, HM
    [J]. BIOCHEMICAL PHARMACOLOGY, 2002, 63 (05) : 897 - 908
  • [23] Sulforhodamine B colorimetric assay for cytotoxicity screening
    Vichai, Vanicha
    Kirtikara, Kanyawim
    [J]. NATURE PROTOCOLS, 2006, 1 (03) : 1112 - 1116
  • [24] Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(ε-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells
    Xiong, Xiao-Bing
    Mahmud, Abdullah
    Uludag, Hasan
    Lavasanifar, Afsaneh
    [J]. BIOMACROMOLECULES, 2007, 8 (03) : 874 - 884
  • [25] Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge
    Yamamoto, Y
    Nagasaki, Y
    Kato, Y
    Sugiyama, Y
    Kataoka, K
    [J]. JOURNAL OF CONTROLLED RELEASE, 2001, 77 (1-2) : 27 - 38
  • [26] Amphotericin B-loaded poly(ethylene glycol)-poly(lactide) micelles:: Preparation, freeze-drying, and in vitro release
    Yang, Zhuo Li
    Li, Xin Ru
    Yang, Ke Wei
    Liu, Yan
    [J]. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2008, 85A (02) : 539 - 546
  • [27] Yasukawa H, 1999, INT OFFSHORE POLAR E, P100
  • [28] Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth
    Yokoyama, Y
    Ramakrishnan, S
    [J]. CANCER, 2005, 104 (02) : 321 - 331
  • [29] Development of amphiphilic diblock copolymers as micellar carriers of taxol
    Zhang, XC
    Jackson, JK
    Burt, HM
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 132 (1-2) : 195 - 206